Compare Global E Online Ltd (GLBE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs TransMedics Group Inc — how do they compare? Global E Online Ltd trades at $40.34 (market cap $6.75B), while TransMedics Group Inc trades at $81.29 (market cap $2.74B). The key difference: Global E Online Ltd is far larger — about 2.5× TransMedics Group Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and TransMedics Group Inc for 24 Days on average.
| GLBE | TMDX | |
|---|---|---|
Market Cap | $6.75B | $2.74B |
Volume | 1,468,708 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $150.42 |
52-Week Low | $27.54 | $61.99 |
Typical Hold Time | 21 Days | 24 Days |
Enterprise Value | $6.24B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.96, up 0.67% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year 2026 outlook. Revenue grew 39% year-over-year in Q2, with an adjusted EBITDA margin expansion to 20.9%. Analyst consensus is strongly bullish with a $48.86 price target, though recent insider selling and a high P/E ratio of 45.65 warrant attention.
The outlook for GLBE is positive based on robust revenue growth and raised guidance, but risks include high valuation multiples and insider selling activity. The stock presents a growth opportunity if execution continues, yet investors should weigh the premium valuation against future earnings potential amid competitive e-commerce markets.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
